期刊
NEUROLOGICAL SCIENCES
卷 42, 期 3, 页码 863-869出版社
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-021-05042-3
关键词
Myasthenia gravis; Antibody; Acetylcholine receptor; Muscle-specific tyrosine kinase; Double-seropositive myasthenia gravis; Subtype
资金
- Project of Guangzhou Science Technology and Innovation Commission [201707010122]
- Guangdong Natural Science Foundation Committee [2017A030313829, 2018A030313449]
- National Key R&D Program of China [2017YFC0907700]
- Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases [2015B050501003]
- Guangdong Provincial Engineering Center For Major Neurological Disease Treatment
- Guangdong Provincial Clinical Research Center for Neurological Diseases
- Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease
The study found that DSP-MG in southern China has more severe symptoms and poor prognosis compared to AChR-MG, with no significant differences compared to MuSK-MG. The researchers speculated that DSP-MG may be a subtype of MuSK-MG.
Introduction This study investigated the characteristics of double-seropositive myasthenia gravis (DSP-MG) in southern China for disease subtype classification. Methods A case-control study was carried out in which the characteristics of DSP-MG patients (n = 17) were compared to those of muscle-specific tyrosine kinase antibody-positive (MuSK)-MG and acetylcholine receptor antibody-positive (AChR)-MG patients (n = 8 and 27, respectively). We also performed a literature review of DSP-MG patients. Results Compared to AChR-MG, DSP-MG had greater bulbar dysfunction (47.1% vs 18.6%, P = 0.04), higher incidence of myasthenia crisis (41.2% vs 14.8%, P = 0.04), more severe Myasthenia Gravis Foundation of America classification at maximum worsening, greater autoantibody abnormalities (70.6% vs 33.3%, P = 0.015), greater need for immunosuppressant treatment (58.8% vs 3.7%, P < 0.001), and worse prognosis with less remission (11.8% vs 55.6%, P = 0.001). There were no differences between DSP-MG and MuSK-MG patients. DSP-MG described in published reports was comparable to MuSK-MG. Discussion DSP-MG in southern China may be a subtype of MuSK-MG.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据